These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 28639229)

  • 21. Comparison of anti-influenza virus activity and pharmacokinetics of oseltamivir free base and oseltamivir phosphate.
    Shin JS; Ku KB; Jang Y; Yoon YS; Shin D; Kwon OS; Go YY; Kim SS; Bae MA; Kim M
    J Microbiol; 2017 Dec; 55(12):979-983. PubMed ID: 29214495
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of oseltamivir treatment of index patients with influenza on secondary household illness in an urban setting in Bangladesh: secondary analysis of a randomised, placebo-controlled trial.
    Fry AM; Goswami D; Nahar K; Sharmin AT; Rahman M; Gubareva L; Trujillo A; Barnes J; Azim T; Bresee J; Luby SP; Brooks WA
    Lancet Infect Dis; 2015 Jun; 15(6):654-62. PubMed ID: 25788164
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Safety, virology and pharmacokinetics of oseltamivir in infants with laboratory-confirmed influenza: a Phase I/II, prospective, open-label, multicentre clinical trial.
    Rath BA; Brzostek J; Guillén S; Niranjan V; Chappey C; Rayner CR; Clinch B
    Antivir Ther; 2015; 20(8):815-25. PubMed ID: 26015411
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A part-randomized study of intravenous oseltamivir in adolescents and adults.
    Várkonyi I; Chappey C; Giraudon M; Burleigh L
    Eur J Clin Microbiol Infect Dis; 2015 Jun; 34(6):1181-8. PubMed ID: 25678009
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacokinetics of high-dose oseltamivir in healthy volunteers.
    Wattanagoon Y; Stepniewska K; Lindegårdh N; Pukrittayakamee S; Silachamroon U; Piyaphanee W; Singtoroj T; Hanpithakpong W; Davies G; Tarning J; Pongtavornpinyo W; Fukuda C; Singhasivanon P; Day NP; White NJ
    Antimicrob Agents Chemother; 2009 Mar; 53(3):945-52. PubMed ID: 19104028
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Safety and Upper Respiratory Pharmacokinetics of the Hemagglutinin Stalk-Binding Antibody VIS410 Support Treatment and Prophylaxis Based on Population Modeling of Seasonal Influenza A Outbreaks.
    Wollacott AM; Boni MF; Szretter KJ; Sloan SE; Yousofshahi M; Viswanathan K; Bedard S; Hay CA; Smith PF; Shriver Z; Trevejo JM
    EBioMedicine; 2016 Mar; 5():147-55. PubMed ID: 27077121
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacokinetics of oseltamivir according to trimester of pregnancy.
    Greer LG; Leff RD; Rogers VL; Roberts SW; McCracken GH; Wendel GD; Sheffield JS
    Am J Obstet Gynecol; 2011 Jun; 204(6 Suppl 1):S89-93. PubMed ID: 21492824
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phase 1 Randomized, Double-Blind, Placebo-Controlled Study of RG7667, an Anticytomegalovirus Combination Monoclonal Antibody Therapy, in Healthy Adults.
    Ishida JH; Burgess T; Derby MA; Brown PA; Maia M; Deng R; Emu B; Feierbach B; Fouts AE; Liao XC; Tavel JA
    Antimicrob Agents Chemother; 2015 Aug; 59(8):4919-29. PubMed ID: 26055360
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Oseltamivir Population Pharmacokinetics in the Ferret: Model Application for Pharmacokinetic/Pharmacodynamic Study Design.
    Reddy MB; Yang KH; Rao G; Rayner CR; Nie J; Pamulapati C; Marathe BM; Forrest A; Govorkova EA
    PLoS One; 2015; 10(10):e0138069. PubMed ID: 26460484
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Ergoferon and oseltamivir in treatment of influenza: results of multicentre randomized comparative clinical trial].
    Aver'ianov AV; Babkin AP; Bart BIa; Volchetskiĭ AL; Minina ES; Kozyrev OA; Kostinov MP; Petrov DV; Sel'kova EP; Putilovskiĭ MA; Nechaev VB; Epshteĭn OI; Andrianova EN
    Antibiot Khimioter; 2012; 57(7-8):23-30. PubMed ID: 23350191
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Oseltamivir: a review of its use in influenza.
    McClellan K; Perry CM
    Drugs; 2001; 61(2):263-83. PubMed ID: 11270942
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and safety of Ergoferon versus oseltamivir in adult outpatients with seasonal influenza virus infection: a multicenter, open-label, randomized trial.
    Rafalsky V; Averyanov A; Bart B; Minina E; Putilovskiy M; Andrianova E; Epstein O
    Int J Infect Dis; 2016 Oct; 51():47-55. PubMed ID: 27616034
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacokinetics of Oral and Intravenous Oseltamivir Treatment of Severe Influenza B Virus Infection Requiring Organ Replacement Therapy.
    Karsch K; Chen X; Miera O; Peters B; Obermeier P; Francis RC; Amann V; Duwe S; Fraaij P; Heider A; de Zwart M; Berger F; Osterhaus A; Schweiger B; Rath B
    Eur J Drug Metab Pharmacokinet; 2017 Feb; 42(1):155-164. PubMed ID: 26994602
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Single and multiple dose pharmacokinetics and safety of ZSP1273, an RNA polymerase PB2 protein inhibitor of the influenza A virus: a phase 1 double-blind study in healthy subjects.
    Hu Y; Li H; Wu M; Zhang H; Ding Y; Peng Y; Li X; Yu Z
    Expert Opin Investig Drugs; 2021 Nov; 30(11):1159-1167. PubMed ID: 34654349
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Oseltamivir-zanamivir bitherapy compared to oseltamivir monotherapy in the treatment of pandemic 2009 influenza A(H1N1) virus infections.
    Escuret V; Cornu C; Boutitie F; Enouf V; Mosnier A; Bouscambert-Duchamp M; Gaillard S; Duval X; Blanchon T; Leport C; Gueyffier F; Van Der Werf S; Lina B
    Antiviral Res; 2012 Nov; 96(2):130-7. PubMed ID: 22909899
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacokinetics and Exposure-Response Analysis of RG7667, a Combination of Two Anticytomegalovirus Monoclonal Antibodies, in a Phase 2a Randomized Trial To Prevent Cytomegalovirus Infection in High-Risk Kidney Transplant Recipients.
    Deng R; Wang Y; Maia M; Burgess T; McBride JM; Liao XC; Tavel JA; Hanley WD
    Antimicrob Agents Chemother; 2018 Feb; 62(2):. PubMed ID: 29133549
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A clinical trial of intravenous peramivir compared with oral oseltamivir for the treatment of seasonal influenza in hospitalized adults.
    Ison MG; Hui DS; Clezy K; O'Neil BJ; Flynt A; Collis PJ; Simon TJ; Alexander WJ
    Antivir Ther; 2013; 18(5):651-61. PubMed ID: 23111657
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacokinetics and safety of intravenous oseltamivir in infants and children in open-label studies.
    Muñoz FM; Anderson EJ; Deville JG; Clinch B; Kamal MA
    Int J Clin Pharmacol Ther; 2015 Jul; 53(7):531-40. PubMed ID: 26042486
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacokinetics of anti-influenza prodrug oseltamivir in children aged 1-5 years.
    Oo C; Hill G; Dorr A; Liu B; Boellner S; Ward P
    Eur J Clin Pharmacol; 2003 Sep; 59(5-6):411-5. PubMed ID: 12910331
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A randomized, double-blind, placebo-controlled trial evaluating the safety of early oseltamivir treatment among children 0-9 years of age hospitalized with influenza in El Salvador and Panama.
    Dawood FS; Jara J; Gonzalez R; Castillo JM; De León T; Estripeaut D; Luciani K; Sujey Brizuela Y; Barahona A; Cazares RA; Lawson AM; Rodriguez M; de Viana D; Franco D; Castillo M; Fry AM; Gubareva L; Tamura D; Hughes M; Gargiullo P; Clara W; Azziz-Baumgartner E; Widdowson MA
    Antiviral Res; 2016 Sep; 133():85-94. PubMed ID: 27451343
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.